Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin/Tazobactam vs Ampicillin/Sulbactam in Diabetic Foot Infections
NCT00044746Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2000
- Primary completion
- Jan 2003
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam in diabetic foot infection (DFI) (2 arms), sponsored by Pfizer. Primary endpoint: Clinical Efficacy Rate (Cure or Improvement). Started Oct 2000; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on NCT00044746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044746.